The nation of Zimbabwe has turned down a substantial American healthcare agreement valued at $367m (272 million pounds) over five years because of Washington's demand for confidential biological samples.
The decision was revealed after a internal memorandum from December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the agreement was "skewed".
An official spokesperson has since explained that the United States was seeking biological samples for research and profit while was unwilling to share the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable task of ending our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had furnished more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged further talks to secure a agreement suitable to all parties so the nation's critical HIV programme can be sustained.
Wider Implications
Zimbabwe's decision follows a comparable case in neighbouring Kenya, where a court halted a similar deal with the US after concerns were filed about the security of citizens' medical information.
Since resuming office recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
The agency had managed aid for the American government, but Trump argued its expenditure was "inefficient" and his administration was seeking government-to-government agreements to boost transparency and responsibility.
Based on statements, 16 nations in Africa have to date agreed to similar health pacts, constituting over $18.3bn in new funding.
Details of the Declined Agreement
The funds for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this cooperation would have delivered immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on HIV treatment via US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana maintained the arrangement was "unequal".
"Our nation was requested to provide its genetic material and health information indefinitely, without any equivalent guarantee of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," his statement read.
"In essence, our country would provide the basic resources for scientific discovery with no certainty that the resulting innovations would be available to our citizens if a future disease outbreak emerge."
National Interest and Global Health
Mangwana further said that the American exit from the global health body and its push of one-on-one deals were upending frameworks already set up through the global health agency.
Mangwana cited its Pandemic Benefit-Sharing framework created to manage potential global health emergencies.
"This mechanism is intended to ensure that when a country contributes its data, the benefits – such as medicines and cures – are shared equitably, not commercialised solely by those with the capability to develop them."
These objections regarding the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We are open to continued discussions with our American counterparts on how future co-operation could be structured in a manner that respects the sovereignty and interests of each country."
Health Experts Response
Medical experts said it acknowledged the official position, but suggested that negotiations need to persist since much of the country's HIV programmes depended on foreign aid.
"In cases where technical issues exist, such as those involving data governance or implementation frameworks, these can frequently be addressed through detailed discussion and mutually agreed protections," it added.
This impasse emphasises the continuing challenges between receiving vital international aid and protecting local interests in an ever more data-driven world.